Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
1078 Mutational signatures as mechanistic biomarkers of tumor immunity: associations with TMB, PD-L1 and immune phenotypes across cancer types
- 1Boehringer Ingelheim GmbH, Biberach an der Riß, Baden-Württemberg, Germany
- 2Institute for Applied Science and Health, Applied University Coburg, Coburg, Bavaria, Germany
Related
- Germline structural variation involving gynecologic and breast cancers reveals polygenic signatures of tumor mutational load
- Chromosomal mutational signatures of DNA damaging agents at single cell resolution
- Global evolutionary dynamics of peste des petits ruminants virus reveals geographic lineage structuring and clade-defining mutational signatures
- Sepsis-associated endothelial dysfunction: clinical phenotypes, biomarkers, bedside evidence, and translational implications
- Blood Cytokine Profiling Reveals Distinct Inflammatory Signatures in Phenotypes A and B of Polyendocrine Metabolic Ovarian Syndrome (PMOS; formerly PCOS).
BibTeX
@article{nath20261078,
title = {{1078 Mutational signatures as mechanistic biomarkers of tumor immunity: associations with TMB, PD-L1 and immune phenotypes across cancer types}},
author = {Neetika Nath and Stefan Simm},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.1078},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.1078},
note = {CC BY},
}
RIS
TY - JOUR
TI - 1078 Mutational signatures as mechanistic biomarkers of tumor immunity: associations with TMB, PD-L1 and immune phenotypes across cancer types
AU - Neetika Nath
AU - Stefan Simm
PY - 2026
DA - 2026/11/04
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.1078
UR - https://doi.org/10.1136/jitc-2026-sitc2026.1078
SN - 2051-1426
ER -